Iceland - Women's share of population ages 15+ living with HIV (%)

Women's share of population ages 15+ living with HIV (%) in Iceland was 27.30 as of 2020. Its highest value over the past 30 years was 27.30 in 2020, while its lowest value was 9.80 in 1990.

Definition: Prevalence of HIV is the percentage of people who are infected with HIV. Female rate is as a percentage of the total population ages 15+ who are living with HIV.

Source: UNAIDS estimates.

See also:

Year Value
1990 9.80
1991 11.30
1992 11.10
1993 14.00
1994 15.00
1995 15.60
1996 17.40
1997 18.70
1998 19.80
1999 20.20
2000 21.20
2001 21.10
2002 22.30
2003 22.60
2004 22.90
2005 23.60
2006 23.70
2007 24.20
2008 24.20
2009 24.60
2010 25.00
2011 25.20
2012 25.60
2013 25.90
2014 26.30
2015 26.50
2016 26.70
2017 27.10
2018 27.10
2019 27.30
2020 27.30

Limitations and Exceptions: The limited availability of data on health status is a major constraint in assessing the health situation in developing countries. Surveillance data are lacking for many major public health concerns. Estimates of prevalence and incidence are available for some diseases but are often unreliable and incomplete. National health authorities differ widely in capacity and willingness to collect or report information.

Statistical Concept and Methodology: HIV prevalence rates reflect the rate of HIV infection in each country's population. Low national prevalence rates can be misleading, however. They often disguise epidemics that are initially concentrated in certain localities or population groups and threaten to spill over into the wider population. In many developing countries most new infections occur in young adults, with young women especially vulnerable. Data on HIV are from the Joint United Nations Programme on HIV/AIDS (UNAIDS). Changes in procedures and assumptions for estimating the data and better coordination with countries have resulted in improved estimates of HIV and AIDS. The models, which are routinely updated, track the course of HIV epidemics and their impact, making full use of information in HIV prevalence trends from surveillance data as well as survey data. The models take into account reduced infectivity among people receiving antiretroviral therapy (which is having a larger impact on HIV prevalence and allowing HIV-positive people to live longer) and allow for changes in urbanization over time in generalized epidemics. The estimates include plausibility bounds, which reflect the certainty associated with each of the estimates.

Aggregation method: Weighted average

Periodicity: Annual

Classification

Topic: Health Indicators

Sub-Topic: Risk factors